Simbrinza

in trials Simbrinza was able to decrease it by 23-37 per cent. ... Simbrinza's EU launch will start in the UK later this quarter, followed by other European markets in the remainder of 2014 and in 2015.

Finally, Novartis' eyecare subsidiary Alcon got a green light for its combination glaucoma therapy Simbrinza (brinzolamide/brimonidine - first approved in the US last year - while Veloxis Pharma got the nod for

Jimenez also said Novartis had a fertile quarter in terms of its pipeline, with four approvals including Ilaris (canakinumab) for systemic juvenile idiopathic arthritis, Simbrinza (brinzolamide/brimonidine tartrate) for glaucoma, Lucentis